Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Cost of Revenue: 2009-2024

Historic Cost of Revenue for Vanda Pharmaceuticals (VNDA) over the last 14 years, with Dec 2024 value amounting to $11.3 million.

  • Vanda Pharmaceuticals' Cost of Revenue rose 15.80% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.8 million, marking a year-over-year decrease of 3.14%. This contributed to the annual value of $11.3 million for FY2024, which is 23.53% down from last year.
  • Per Vanda Pharmaceuticals' latest filing, its Cost of Revenue stood at $11.3 million for FY2024, which was down 23.53% from $14.8 million recorded in FY2023.
  • In the past 5 years, Vanda Pharmaceuticals' Cost of Revenue ranged from a high of $25.6 million in FY2021 and a low of $11.3 million during FY2024.
  • Its 3-year average for Cost of Revenue is $16.8 million, with a median of $14.8 million in 2023.
  • Its Cost of Revenue has fluctuated over the past 5 years, first increased by 9.69% in 2021, then slumped by 39.07% in 2023.
  • Vanda Pharmaceuticals' Cost of Revenue (Yearly) stood at $23.4 million in 2020, then climbed by 9.69% to $25.6 million in 2021, then declined by 5.26% to $24.3 million in 2022, then slumped by 39.07% to $14.8 million in 2023, then declined by 23.53% to $11.3 million in 2024.